Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2014 Jan 15;24(2):462-6. doi: 10.1016/j.bmcl.2013.12.048. Epub 2013 Dec 18.

Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.

Author information

1
R&D Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina Km 30,400, I-00040 Pomezia (RM), Italy. Electronic address: giuseppe.giannini@sigma-tau.it.
2
R&D Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Via Pontina Km 30,400, I-00040 Pomezia (RM), Italy.
3
Scientia Advice di Roberto Artali, 20832 Desio (MB), Italy.
4
Department of Food, Environmental and Nutritional Sciences, Division of Chemistry and Molecular Biology, Università di Milano, Via Celoria 2, 20133 Milano, Italy.

Abstract

Poly(ADP-ribose)polymerase-I (PARP-1) enzyme is involved in maintaining DNA integrity and programmed cell death. A virtual screening of commercial libraries led to the identification of five novel scaffolds with inhibitory profile in the low nanomolar range. A hit-to-lead optimization led to the identification of a group of new potent PARP-1 inhibitors, acyl-piperazinylamides of 3-(4-oxo-3,4-dihydro-quinazolin-2-yl)-propionic acid. Molecular modeling studies highlighted the preponderant role of the propanoyl side chain.

KEYWORDS:

3-(4-Oxo-3,4-dihydro-quinazolin-2-yl)-propionamides; Anticancer; Hit-to-lead optimization; Molecular modeling; PARP-1 inhibitors; Virtual screening of commercial libraries

PMID:
24388690
DOI:
10.1016/j.bmcl.2013.12.048
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Archivio Istituzionale della Ricerca Unimi
Loading ...
Support Center